novartis
Swiss pharmaceutical giant Novartis saw its shares jump after reporting solid first-quarter profits and sales growth on Tuesday. Shares were up more than 4% in Switzerland and more than 5% in pre-market activity in New York. The company also raised its fiscal 2024 outlook for growth in sales and core operating income. Further, Novartis said it plans to propose Giovanni Caforio as chair of the board of directors at its annual general meeting in 2025. The 12-year term of Joerg Reinhardt is set to end as scheduled in 2025, when he will retire and not be available for re-election. Novartis chief e...
DPA Breaking News
Swiss pharmaceutical giant Novartis saw its shares jump after reporting solid first-quarter profits and sales growth on Tuesday. Shares were up more than 4% in Switzerland and more than 5% in pre-market activity in New York. The company also raised its fiscal 2024 outlook for growth in sales and core operating income. Further, Novartis said it plans to propose Giovanni Caforio as chair of the board of directors at its annual general meeting in 2025. The 12-year term of Joerg Reinhardt is set to end as scheduled in 2025, when he will retire and not be available for re-election. Novartis chief e...
DPA
Swiss pharmaceutical giant Novartis saw its shares jump after reporting solid first-quarter profits and sales growth on Tuesday. Shares were up more than 4% in Switzerland and more than 5% in pre-market activity in New York. The company also raised its fiscal 2024 outlook for growth in sales and core operating income. Further, Novartis said it plans to propose Giovanni Caforio as chair of the board of directors at its annual general meeting in 2025. The 12-year term of Joerg Reinhardt is set to end as scheduled in 2025, when he will retire and not be available for re-election. Novartis chief e...
DPA International
German biopharmaceutical company MorphoSys AG recommended on Thursday that an offer by Swiss pharmaceutical firm Novartis be accepted. MorphoSys' management board and supervisory board recommended that shareholders tender their MorphoSys shares. Novartis has offered MorphoSys shareholders €68 ($72.90) per share in cash, representing a total equity value of €2.7 billion. MorphoSys and Novartis maintain their expectation that the closing of the takeover offer will take place in the first half of 2024. The takeover offer requires a minimum acceptance threshold of 65% of MorphoSys' share capital. ...
DPA
German biopharmaceutical company MorphoSys AG recommended on Thursday that an offer by Swiss pharmaceutical firm Novartis be accepted. MorphoSys' management board and supervisory board recommended that shareholders tender their MorphoSys shares. Novartis has offered MorphoSys shareholders €68 ($72.90) per share in cash, representing a total equity value of €2.7 billion. MorphoSys and Novartis maintain their expectation that the closing of the takeover offer will take place in the first half of 2024. The takeover offer requires a minimum acceptance threshold of 65% of MorphoSys' share capital. ...
DPA International
German biopharmaceutical company MorphoSys AG recommended on Thursday that an offer by Swiss pharmaceutical firm Novartis be accepted. MorphoSys' management board and supervisory board recommended that shareholders tender their MorphoSys shares. Novartis has offered MorphoSys shareholders €68 ($72.90) per share in cash, representing a total equity value of €2.7 billion. MorphoSys and Novartis maintain their expectation that the closing of the takeover offer will take place in the first half of 2024. The takeover offer requires a minimum acceptance threshold of 65% of MorphoSys' share capital. ...
DPA Breaking News
German antitrust regulators have approved the takeover of German biotech company Morphosys by the Swiss pharmaceutical firm Novartis. Germany's Federal Cartel Office announced its approval of the transaction on Tuesday. Morphosys, which is headquartered near Munich, manufactures drugs to treat the blood cancers leukaemia. Andreas Mundt, who heads the regulatory agency, said officials had examined very carefully whether the merger would affect competition in the research and development of new drugs to treat leukaemia. Mundt said the agency's review found "no serious competition concerns." Many...
DPA International
German antitrust regulators have approved the takeover of German biotech company Morphosys by the Swiss pharmaceutical firm Novartis. Germany's Federal Cartel Office announced its approval of the transaction on Tuesday. Morphosys, which is headquartered near Munich, manufactures drugs to treat the blood cancers leukaemia. Andreas Mundt, who heads the regulatory agency, said officials had examined very carefully whether the merger would affect competition in the research and development of new drugs to treat leukaemia. Mundt said the agency's review found "no serious competition concerns." Many...
DPA
German antitrust regulators have approved the takeover of German biotech company Morphosys by the Swiss pharmaceutical firm Novartis. Germany's Federal Cartel Office announced its approval of the transaction on Tuesday. Morphosys, which is headquartered near Munich, manufactures drugs to treat the blood cancers leukaemia. Andreas Mundt, who heads the regulatory agency, said officials had examined very carefully whether the merger would affect competition in the research and development of new drugs to treat leukaemia. Mundt said the agency's review found "no serious competition concerns." Many...
DPA Breaking News
Following is the unofficial transcript of a CNBC exclusive interview with Novartis (NYSE:NVS) CEO Dr. Vas Narasimhan on CNBC’s “Squawk on the Street” (M-F 9AM – 11AM ET) today, Wednesday, January 12. Following is a link to video on CNBC.com: Q4 2021 hedge fund letters, conferences and more Novartis CEO: We’re Moving Toward Filing Covid Drug From Molecular Partners With FDACARL QUINTANILLA: Day three of the JPMorgan Healthcare Conference. Meg Tirrell joins us with a special guest. Hey Meg. MEG TIRRELL: Hey Carl. Dr. Vas Narasimhan, the CEO of Novartis, joins us now. Vas, it’s great to see you. ...
ValueWalk
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら